Log in

CBLL Ceribell, Inc. NASDAQ · United States

Ceribell (CBLL) news

Ceribell, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CBLL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Ceribell news

We have not published a story on Ceribell yet. When there is news, it will appear here.

Ceribell annual financials

LineFY2025FY2024
Revenue$89.1 million$65.4 million
Research and development$19.1 million$13.6 million
Net income (loss)-$53.4 million-$40.5 million
Cash from operations-$40.8 million-$35.0 million
Cash and equivalents$40.5 million$194.4 million
Short-term investments$118.8 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $32.7 million, plus short-term investments of $96.6 million, $129.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Ceribell

What is the ticker symbol of Ceribell?

Ceribell, Inc. trades under the ticker CBLL on NASDAQ.

Where is Ceribell listed?

Ceribell, Inc. is listed on NASDAQ.

Which country or territory is Ceribell listed under?

Our directory records Ceribell, Inc. under United States.

Does aibio.space cover Ceribell?

aibio.space lists Ceribell, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Ceribell's revenue last year?

$89.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Ceribell profitable?

Ceribell, Inc. reported a net loss of $53.4 million for the fiscal year ended Dec 31, 2025, and used $40.8 million of cash in operations, per its annual report to the SEC.

How much does Ceribell spend on research and development?

$19.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Ceribell have?

$129.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

Investor discussion: Ceribell

Members talk about Ceribell (CBLL). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Ceribell, newest first. Each line links the filing it comes from.

  1. Legal

    Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CBLL on TradingView.

Listing details

Ceribell, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CBLL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Ceribell, Inc.
Ticker
CBLL
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.